NovoMix 30 FlexPen

Manufacturer: Novo Nordisk

Pharmaceutical name: Insulin Aspart

Pack: 1 pack (5 pens x 3ml (100 iu/ml))

NovoMix 30 FlexPen (which are prefilled pens) contains 30% soluble (rapid-acting) insulin aspart and 70% protamine-crystallised (intermediate-acting) insulin aspart as its active ingredient. It is utilized in the management of diabetes and is suitable for patients aged 10 and older.

 

NovoMix 30 FlexPen is administered via injection under the skin of the abdominal area (belly) or thigh. It can also be injected into the deltoid (shoulder) or gluteal (buttock) regions if preferred. Regular monitoring of the patient’s blood glucose (sugar) levels is necessary to determine the lowest effective dosage. NovoMix is generally administered right before a meal but may be given afterward if needed. The typical dosage ranges from 0.5 to 1.0 U per kilogram of body weight daily.

 

In cases of type 2 diabetes, NovoMix may be used alone or in conjunction with metformin (another diabetes medication). Additionally, NovoMix 30 can be combined with other oral antidiabetes treatments; however, it should only be used with pioglitazone after a doctor has assessed the patient's potential for fluid-related side effects. For further details, refer to the summary of product characteristics (also part of the EPAR).

 

Patients are able to self-administer NovoMix after receiving proper training.

 

Diabetes is a condition where the body does not produce enough insulin to regulate blood glucose levels. NovoMix serves as a replacement insulin that closely resembles the insulin naturally produced by the pancreas.

 

The active ingredient, insulin aspart, is generated through recombinant DNA technology and is produced by yeast that has been modified to include a gene (DNA) allowing it to manufacture insulin aspart.

 

Insulin aspart is only slightly different from human insulin. This alteration allows it to be absorbed more rapidly by the body compared to human insulin, leading to quicker action. NovoMix consists of insulin aspart in two forms: a soluble form that acts within 10 minutes of injection and a crystallised form that is absorbed more gradually throughout the day. This replacement insulin functions similarly to naturally occurring insulin, facilitating glucose uptake by cells from the bloodstream. By maintaining optimal blood glucose levels, it helps alleviate the symptoms and complications associated with diabetes.

 

NovoMix 30 FlexPen demonstrated nearly identical outcomes to biphasic human insulin 30 at the conclusion of the research. Combining NovoMix 30 with other antidiabetes medications also resulted in superior blood glucose control compared to the use of those medications alone.

 

The most frequently reported side effect of NovoMix (observed in more than 10% of patients) is hypoglycaemia (low blood glucose levels). For the complete list of reported side effects associated with NovoMix, please consult the Package Leaflet.

 

NovoMix 30 FlexPen should not be administered to individuals who may have a hypersensitivity (allergy) to insulin aspart or any other components. Dosages of NovoMix may also need to be modified when used alongside other medications that could influence blood glucose levels. For the full list of such medications, please refer to the Package Leaflet.